company background image
CVAC logo

CureVac WBAG:CVAC Stock Report

Last Price

€2.79

Market Cap

€617.0m

7D

-7.6%

1Y

-25.8%

Updated

22 Dec, 2024

Data

Company Financials +

CVAC Stock Overview

A biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). More details

CVAC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

CureVac N.V. Competitors

Price History & Performance

Summary of share price highs, lows and changes for CureVac
Historical stock prices
Current Share PriceUS$2.79
52 Week HighUS$4.62
52 Week LowUS$2.10
Beta2.59
1 Month Change7.89%
3 Month Change-1.27%
1 Year Change-25.80%
3 Year Change-91.36%
5 Year Changen/a
Change since IPO-93.74%

Recent News & Updates

Recent updates

Shareholder Returns

CVACAT BiotechsAT Market
7D-7.6%1.0%-1.4%
1Y-25.8%11.4%-1.6%

Return vs Industry: CVAC underperformed the Austrian Biotechs industry which returned 11.4% over the past year.

Return vs Market: CVAC underperformed the Austrian Market which returned -1.6% over the past year.

Price Volatility

Is CVAC's price volatile compared to industry and market?
CVAC volatility
CVAC Average Weekly Movement6.8%
Biotechs Industry Average Movement7.5%
Market Average Movement3.8%
10% most volatile stocks in AT Market6.2%
10% least volatile stocks in AT Market2.1%

Stable Share Price: CVAC's share price has been volatile over the past 3 months compared to the Austrian market.

Volatility Over Time: CVAC's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Austrian stocks.

About the Company

FoundedEmployeesCEOWebsite
20001,086Alexander Zehnderwww.curevac.com

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer.

CureVac N.V. Fundamentals Summary

How do CureVac's earnings and revenue compare to its market cap?
CVAC fundamental statistics
Market cap€617.00m
Earnings (TTM)-€278.43m
Revenue (TTM)€65.86m

9.4x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CVAC income statement (TTM)
Revenue€65.86m
Cost of Revenue€152.13m
Gross Profit-€86.27m
Other Expenses€192.16m
Earnings-€278.43m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.24
Gross Margin-131.00%
Net Profit Margin-422.77%
Debt/Equity Ratio0%

How did CVAC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 16:08
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CureVac N.V. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charlie YangBofA Global Research
Geoffrey MeachamBofA Global Research
Martin AusterCredit Suisse